TC BIOPHARM HOLDINGS PLC-ADR (TCBP)
US87807D4007 - ADR
We assign a fundamental rating of 1 out of 10 to TCBP. TCBP was compared to 565 industry peers in the Biotechnology industry. TCBP has a bad profitability rating. Also its financial health evaluation is rather negative. TCBP has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
TCBP had negative earnings in the past year.
In the past year TCBP has reported a negative cash flow from operations.
In the past 5 years TCBP always reported negative net income.
In the past 5 years TCBP always reported negative operating cash flow.
1.2 Ratios
TCBP has a worse Return On Assets (-71.77%) than 66.55% of its industry peers.
TCBP has a Return On Equity of -293.88%. This is in the lower half of the industry: TCBP underperforms 73.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.77% | ||
| ROE | -293.88% | ||
| ROIC | N/A |
ROA(3y)-82.72%
ROA(5y)-76.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TCBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TCBP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TCBP has been increased compared to 1 year ago.
TCBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
TCBP has an Altman-Z score of -8.05. This is a bad value and indicates that TCBP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.05, TCBP is doing worse than 69.73% of the companies in the same industry.
A Debt/Equity ratio of 1.07 is on the high side and indicates that TCBP has dependencies on debt financing.
TCBP's Debt to Equity ratio of 1.07 is on the low side compared to the rest of the industry. TCBP is outperformed by 78.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.05 |
ROIC/WACCN/A
WACC2.73%
2.3 Liquidity
A Current Ratio of 1.09 indicates that TCBP should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.09, TCBP is doing worse than 86.90% of the companies in the same industry.
TCBP has a Quick Ratio of 1.09. This is a normal value and indicates that TCBP is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.09, TCBP is not doing good in the industry: 84.96% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.09 | ||
| Quick Ratio | 1.09 |
3. Growth
3.1 Past
TCBP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1607.25%.
The Revenue for TCBP has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-1607.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.9%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, TCBP will show a very strong growth in Earnings Per Share. The EPS will grow by 41.42% on average per year.
Based on estimates for the next years, TCBP will show a very negative growth in Revenue. The Revenue will decrease by -41.42% on average per year.
EPS Next Y99.78%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
TCBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TCBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TCBP's earnings are expected to grow with 41.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for TCBP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TC BIOPHARM HOLDINGS PLC-ADR
NASDAQ:TCBP (12/20/2024, 8:00:00 PM)
After market: 0.65 -0.01 (-1.52%)0.66
+0 (+0.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.77%
Inst Owner Change-90.24%
Ins Owners0%
Ins Owner Change0%
Market Cap5.42M
Analysts82.86
Price TargetN/A
Short Float %3.6%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.15 | ||
| P/tB | 3.07 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-1.95
FCFYN/A
OCF(TTM)-1.86
OCFYN/A
SpS0
BVpS0.31
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.77% | ||
| ROE | -293.88% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-82.72%
ROA(5y)-76.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.09 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z | -8.05 |
F-Score1
WACC2.73%
ROIC/WACCN/A
Cap/Depr(3y)28.28%
Cap/Depr(5y)69.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1607.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.9%
EPS Next Y99.78%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.79%
OCF growth 3YN/A
OCF growth 5YN/A